ASO Author Reflection: The End of the Tower of Babel in Pseudomyxoma Peritonei.

Abstract

Peritoneal pseudomyxoma (PMP) is a rare disease that is treated in referral centres via cytoreductive surgery in association with hyperthermic Intraperitoneal chemotherapy (HIPEC). Given its particular biological and histological characteristics, the nomenclature used to describe PMP has not yet been standardized and therefore several histological classifications are available, including those by Ronnett et al. in 1995,1 Bradley et al. in 2006,2 the WHO classification published in 2010,3 and the American Joint Committee on Cancer (AJCC) 8th edition in 2017.4 This Tower of Babel in PMP has made it very difficult to compare and share the data between different centres.